Assertio Therapeutics Inc (ASRT) - Total Assets
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) holds total assets worth $211.30 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Assertio Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Assertio Therapeutics Inc - Total Assets Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See ASRT total equity for net asset value and shareholders' equity analysis.
Assertio Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Assertio Therapeutics Inc's total assets of $211.30 Million consist of 81.2% current assets and 18.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.8% |
| Accounts Receivable | $120.11 Million | 45.0% |
| Inventory | $24.12 Million | 9.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $48.91 Million | 18.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Assertio Therapeutics Inc (ASRT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Assertio Therapeutics Inc's current assets represent 81.2% of total assets in 2025, an increase from 66.7% in 1996.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2025, up from 0.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 45.0% of total assets.
Assertio Therapeutics Inc Competitors by Total Assets
Key competitors of Assertio Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Assertio Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.82 | 1.66 | 1.02 |
| Quick Ratio | 1.57 | 1.35 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $75.28 Million | $84.72 Million | $2.43 Million |
Assertio Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Assertio Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.00 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | -6.2% |
| Total Assets | $266.97 Million |
| Market Capitalization | $151.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Assertio Therapeutics Inc's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Assertio Therapeutics Inc's assets decreased by 6.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual total assets of Assertio Therapeutics Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $266.97 Million | -6.24% |
| 2024-12-31 | $284.73 Million | -0.59% |
| 2023-12-31 | $286.42 Million | -30.80% |
| 2022-12-31 | $413.91 Million | +26.75% |
| 2021-12-31 | $326.55 Million | +7.67% |
| 2020-12-31 | $303.27 Million | -42.47% |
| 2019-12-31 | $527.17 Million | -43.49% |
| 2018-12-31 | $932.87 Million | -10.18% |
| 2017-12-31 | $1.04 Billion | -15.24% |
| 2016-12-31 | $1.23 Billion | -10.13% |
| 2015-12-31 | $1.36 Billion | +91.75% |
| 2014-12-31 | $711.07 Million | +39.79% |
| 2013-12-31 | $508.65 Million | +259.08% |
| 2012-12-31 | $141.65 Million | -13.82% |
| 2011-12-31 | $164.37 Million | +88.87% |
| 2010-12-31 | $87.03 Million | -4.97% |
| 2009-12-31 | $91.58 Million | -3.68% |
| 2008-12-31 | $95.08 Million | +17.90% |
| 2007-12-31 | $80.64 Million | +53.27% |
| 2006-12-31 | $52.62 Million | -20.73% |
| 2005-12-31 | $66.38 Million | +190.26% |
| 2004-12-31 | $22.87 Million | -52.05% |
| 2003-12-31 | $47.69 Million | +105.76% |
| 2002-12-31 | $23.18 Million | +165.00% |
| 2001-12-31 | $8.75 Million | +0.16% |
| 2000-12-31 | $8.73 Million | -61.08% |
| 1999-12-31 | $22.43 Million | +117.81% |
| 1998-12-31 | $10.30 Million | +123.91% |
| 1997-12-31 | $4.60 Million | +1433.33% |
| 1996-12-31 | $300.00K | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more